@article{ref1,
title="A comprehensive review of daridorexant, a dual-orexin receptor antagonist as new approach for the treatment of insomnia",
journal="Molecules",
year="2022",
author="Ziemichód, Wojciech and Grabowska, Karolina and Kurowska, Antonina and Biała, Grazyna",
volume="27",
number="18",
pages="6041-6041",
abstract="Insomnia affects 4.4-4.8% of the world's population, but because the effect of hypnotic drugs is limited and may cause harmful side-effects, scientists are turning their attention to developing drugs that act on the orexin system. Daridorexant, a selective dual-orexin receptor antagonist (DORA), has exhibited promising results in both animal and human studies. Its activity was evaluated based on the physiology-based pharmacodynamic and pharmacokinetic model. The use of daridorexant is considered safe, with no clinically significant side-effects including deprivation of next-morning residual effects. In this manuscript we conducted a comprehensive review of daridorexant including pharmacodynamics, animal and human research, pharmacokinetics and safety.<p /> <p>Language: en</p>",
language="en",
issn="1420-3049",
doi="10.3390/molecules27186041",
url="http://dx.doi.org/10.3390/molecules27186041"
}